Publicacións en colaboración con investigadores/as de Instituto de Investigación Sanitaria de Santiago de Compostela (72)

2024

  1. 2-Aryladenine Derivatives as a Potent Scaffold for Adenosine Receptor Antagonists: The 6-Morpholino Derivatives

    Molecules, Vol. 29, Núm. 11

  2. A journey through the history of PEGylated drug delivery nanocarriers

    Drug Delivery and Translational Research, Vol. 14, Núm. 8, pp. 2026-2031

  3. Bioequivalence risk assessment of oral formulations containing racemic ibuprofen through a chiral physiologically based pharmacokinetic model of ibuprofen enantiomers

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 199

  4. Clinical Effectiveness, Safety, and Compliance of Two Compounded Formulations of Tacrolimus Eye Drops: An Open-Label, Sequential Prospective Study

    International Journal of Molecular Sciences, Vol. 25, Núm. 18

  5. Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study

    Diseases, Vol. 12, Núm. 10

  6. Edoxaban treatment in a post-infarction experimental model

    European Journal of Pharmacology, Vol. 962

  7. Engineering hyaluronic acid-based nanoassemblies for monoclonal antibody delivery – design, characterization, and biological insights

    Nano Research, Vol. 17, Núm. 10, pp. 9111-9125

  8. Nanotechnology-assisted intracellular delivery of antibody as a precision therapy approach for KRAS-driven tumors

    Journal of Controlled Release, Vol. 373, pp. 277-292

  9. Preclinical characterization of endotoxin-induced uveitis models using OCT, PET/CT and proteomics

    International Journal of Pharmaceutics, Vol. 662

  10. Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab

    Pharmaceuticals, Vol. 17, Núm. 2

  11. Role of CYP2D6 and CYP3A4 polymorphisms on aripiprazole and dehydroaripiprazole concentrations in patients undergoing long-acting treatment

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 135

  12. The Effect of Systemic Parameters and Baseline Characteristics in Short-Term Response Analysis with Intravitreal Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration

    Pharmaceutics, Vol. 16, Núm. 1

  13. Towards Precision Medicine in Clinical Practice: Alinity C vs. UHPLC-MS/MS in Plasma Aripiprazole Determination

    Pharmaceutics, Vol. 16, Núm. 1

  14. Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling

    Psychiatry Research, Vol. 333

2023

  1. A continuous in silico learning strategy to identify safety liabilities in compounds used in the leather and textile industry

    Archives of Toxicology, Vol. 97, Núm. 4, pp. 1091-1111

  2. Ampicillin Stability in a Portable Elastomeric Infusion Pump: A Step Forward in Outpatient Parenteral Antimicrobial Therapy

    Pharmaceutics, Vol. 15, Núm. 8

  3. Association of cyclophilins and cardiovascular risk factors in coronary artery disease

    Frontiers in Physiology, Vol. 14

  4. Correction: A Review of Population Pharmacokinetic Analyses of Linezolid (Clinical Pharmacokinetics, (2022), 61, 6, (789-817), 10.1007/s40262-022-01125-2)

    Clinical Pharmacokinetics

  5. Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems, Part II: Long-Term Stability and Clinical Ocular Biopermanence

    Pharmaceutics, Vol. 15, Núm. 11

  6. Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase

    Primary Care Diabetes, Vol. 17, Núm. 4, pp. 366-372